BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• 

  Approvals

  FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease

  The approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regeneron’s recently approved Pasatru and Ipsen’s Sohonos.

  September 28, 2026

   · 

  6 min read

   · 

  Michael Gibney
• Press Releases

  Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

  September 28, 2026

   · 

  7 min read
• Press Releases

  Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection

  September 28, 2026

   · 

  11 min read
• Press Releases

  Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

  September 28, 2026

   · 

  5 min read
• Press Releases

  4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

  September 28, 2026

   · 

  9 min read
• Press Releases

  ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

  September 28, 2026

   · 

  6 min read
• Press Releases

  NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

  September 28, 2026

   · 

  6 min read
• Press Releases

  Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer

  September 28, 2026

   · 

  4 min read
• Press Releases

  ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

  September 28, 2026

   · 

  8 min read
• Press Releases

  IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer’s Trial; Topline Results Expected Q4 2026

  September 28, 2026

   · 

  4 min read